Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Zhang, Kang Jian ^a   Qian, Jing ^b   Wang, Shi Bing ^b   Yang, Yi ^c  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

AD55 Apoptin; antitumor effect; apoptosis; Cancer targeting gene viro therapy; hepatocelluar carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; APOPTIN; DNA NUCLEOTIDYLEXOTRANSFERASE; HOE 33342; LONTUCIREV; RECOMBINANT ADENOVIRUS VECTOR 55; UNCLASSIFIED DRUG; CAPSID PROTEIN; ONCOLYTIC VIRUS; VP3 PROTEIN, CHICKEN ANEMIA VIRUS;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL LINE; DRUG SAFETY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; STAINING; TUMOR VOLUME; VIRAL GENE THERAPY; WESTERN BLOTTING; XENOGRAFT; ADENOVIRUS; ANIMAL; CELL STRAIN HEK293; CELL SURVIVAL; GENE THERAPY; GENE VECTOR; GENETICS; LIVER TUMOR; METHODOLOGY; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; TUMOR CELL LINE;

ADENOVIRIDAE; MUS MUSCULUS;

ADENOVIRIDAE; ANIMALS; CAPSID PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84862809396     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-20     Document Type: Article

References (47)

1. Gene therapy of liver cancer. Hernandez-Alcoceba R, Sangro B, Prieto J, World J Gastroenterol 2006 12 6085 6097 (Pubitemid 44688155)
2. Breakthrough of the year. The runners-up. Science 2009 326 1600 1607
3. Targeting gene-virotherapy of cancer and its prosperity. Liu XY, Cell Res 2006 16 879 886 (Pubitemid 44764197)
4. Gene therapy: adenovirus vectors. Kozarsky KF, Wilson JM, Curr Opin Genet Dev 1993 3 499 503 (Pubitemid 23220755)
5. Replicative adenoviruses for cancer therapy. Alemany R, Balague C, Curiel DT, Nat Biotechnol 2000 18 723 727 (Pubitemid 30460686)
6. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY, Cell Res 2003 13 481 489 (Pubitemid 43231842)
7. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F, Cancer Cell 2004 6 611 623 (Pubitemid 40017704)
8. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, Phipps S, Chiang YL, Hum Gene Ther 1999 10 1721 1733 (Pubitemid 29328216)
9. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y, J Clin Gastroenterol 2000 31 302 308
10. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR, Cancer Res 2001 61 6428 6436 (Pubitemid 32783248)
11. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Arbuthnot P, Bralet MP, Thomassin H, Danan JL, Brechot C, Ferry N, Hepatology 1995 22 1788 1796
12. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Arbuthnot PB, Bralet MP, Le Jossic C, Dedieu JF, Perricaudet M, Brechot C, Ferry N, Hum Gene Ther 1996 7 1503 1514 (Pubitemid 26302205)
13. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Danen-Van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JH, Backendorf C, Quax PH, Van der Eb AJ, Noteborn MH, Proc Natl Acad Sci USA 1997 94 5843 5847 (Pubitemid 27241859)
14. Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb AJ, Noteborn MH, Cancer Res 1995 55 486 489
15. The effect of Bcl-2 on Apoptin in 'normal' vs transformed human cells. Danen-Van Oorschot AA, Zhang Y, Erkeland SJ, Fischer DF, van der Eb AJ, Noteborn MH, Leukemia 1999 13 Suppl 1 75 77
16. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Burek M, Maddika S, Burek CJ, Daniel PT, Schulze-Osthoff K, Los M, Oncogene 2006 25 2213 2222
17. BCL-2 stimulates Apoptin-induced apoptosis. Danen-Van Oorschot AA, van der Eb AJ, Noteborn MH, Adv Exp Med Biol 1999 457 245 249
18. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M, Oncogene 2004 23 1153 1165 (Pubitemid 38269969)
19. PTD4-apoptin protein therapy inhibits tumor growth in vivo. Sun J, Yan Y, Wang XT, Liu XW, Peng DJ, Wang M, Tian J, Zong YQ, Zhang YH, Noteborn MH, Qu S, International journal of cancer 2009 124 2973 2981
20. Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MH, Cornelis JJ, Cancer Gene Ther 2001 8 958 965 (Pubitemid 33140314)
21. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Pietersen AM, van der Eb MM, Rademaker HJ, van den Wollenberg DJ, Rabelink MJ, Kuppen PJ, van Dierendonck JH, van Ormondt H, Masman D, van de Velde CJ, van der Eb AJ, Hoeben RC, Noteborn MH, Gene Ther 1999 6 882 892 (Pubitemid 29243663)
22. Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro. Li X, Jin N, Mi Z, Lian H, Sun L, Zheng H, International journal of cancer 2006 119 2948 2957 (Pubitemid 44846250)
23. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, Wang Y, Zhang J, Zhang Z, Huiwang J, Qian Q, Qian C, Liu X, Hum Gene Ther 2005 16 845 858 (Pubitemid 40982333)
24. Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer. Yu de B, Zhong SY, Yang M, Wang YG, Qian QJ, Zheng S, Liu XY, Cancer Sci 2009 100 678 683
25. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus. Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, Yue XT, Li GC, Liu XY, Hum Gene Ther 2009 20 818 830
26. The lower cytotoxicity of cinnamomin (a type II RIP) is due to its B-chain. Wang BZ, Zou WG, Liu WY, Liu XY, Arch Biochem Biophys 2006 451 91 96
27. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Bendrik C, Robertson J, Gauldie J, Dabrosin C, Cancer Res 2008 68 3405 3412
28. Liver function test abnormalities in anorexia nervosa - cause or effect. Narayanan V, Gaudiani JL, Harris RH, Mehler PS, Int J Eat Disord 2010 43 378 381
29. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F, Science 1996 274 373 376 (Pubitemid 26353341)
30. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H, J Virol 1998 72 9470 9478 (Pubitemid 28520810)
31. Heterochromatin silencing of p53 target genes by a small viral protein. Soria C, Estermann FE, Espantman KC, O'Shea CC, Nature 2010 466 1076 1081
32. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Ohashi M, Kanai F, Tateishi K, Taniguchi H, Marignani PA, Yoshida Y, Shiratori Y, Hamada H, Omata M, Biochem Biophys Res Commun 2001 282 529 535 (Pubitemid 32917903)
33. Cellular promoters incorporated into the adenovirus genome. Effect of viral DNA replication on endogenous and exogenous gene transcription. Babiss LE, Friedman JM, Darnell JE Jr, J Mol Biol 1987 193 643 650 (Pubitemid 17020071)
34. Insulation of a conditionally expressed transgene in an adenoviral vector. Vassaux G, Hurst HC, Lemoine NR, Gene Ther 1999 6 1192 1197 (Pubitemid 29295228)
35. Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Backendorf C, Visser AE, de Boer AG, Zimmerman R, Visser M, Voskamp P, Zhang YH, Noteborn M, Annu Rev Pharmacol Toxicol 2008 48 143 169 (Pubitemid 351756360)
36. Apoptin: specific killer of tumor cells? Tavassoli M, Guelen L, Luxon BA, Gaken J, Apoptosis 2005 10 717 724 (Pubitemid 41187071)
37. The viral protein Apoptin induces apoptosis in UV-C-irradiated cells from individuals with various hereditary cancer-prone syndromes. Zhang YH, Abrahams PJ, van der Eb AJ, Noteborn MH, Cancer Res 1999 59 3010 3015 (Pubitemid 29283145)
38. The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Oro C, Jans DA, Curr Drug Targets 2004 5 179 190 (Pubitemid 38279416)
39. Gene therapy with apoptin induces regression of xenografted human hepatomas. van der Eb MM, Pietersen AM, Speetjens FM, Kuppen PJ, van de Velde CJ, Noteborn MH, Hoeben RC, Cancer Gene Ther 2002 9 53 61 (Pubitemid 34052854)
40. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. Danen-van Oorschot AA, van Der Eb AJ, Noteborn MH, J Virol 2000 74 7072 7078 (Pubitemid 30470691)
41. Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin. Maddika S, Wiechec E, Ande SR, Poon IK, Fischer U, Wesselborg S, Jans DA, Schulze-Osthoff K, Los M, Oncogene 2008 27 3060 3065 (Pubitemid 351668005)
42. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Maddika S, Panigrahi S, Wiechec E, Wesselborg S, Fischer U, Schulze-Osthoff K, Los M, Mol Cell Biol 2009 29 1235 1248
43. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco I, Sawyers CL, Nat Rev Cancer 2002 2 489 501 (Pubitemid 37328931)
44. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK, Cell 2004 116 527 540 (Pubitemid 38264430)
45. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, Los M, J Cell Sci 2005 118 4485 4493 (Pubitemid 41556346)
46. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. Maddika S, Ande SR, Wiechec E, Hansen LL, Wesselborg S, Los M, J Cell Sci 2008 121 979 988 (Pubitemid 351639417)
47. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT, Breast Cancer Res 2009 11 12